Immutep, Capricor Therapeutics, Cyclacel Pharmaceuticals among healthcare movers [Seeking Alpha]
Prenetics Global Limited (NASDAQ: PRE) had its price target lowered by analysts at Cantor Fitzgerald from $10.00 to $9.00. They now have an "overweight" rating on the stock.
Prenetics Announces Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Prenetics Announces Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Prenetics Announces Fourth Quarter and Full Year 2023 Financial Results